Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 489-493

  Goldhirsch, A ^a   Colleoni, M ^a   Coates, A S ^b   Castiglione Gertsch, M ^c   Gelber, R D ^d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Intl Breast Cancer Stud Grp C   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; CMF; Radiotherapy; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0031841505     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008236502420     Document Type: Review

References (25)

1. Overgaard M, Hansen PS, Overgaard J et al. for the Danish Breast Cancer Cooperative Group 82b Trial. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337: 949-55.
2. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-62.
3. Hellman S. Slopping metastases at their source. N Engl J Med 1997; 337: 996-7.
4. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.
5. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
6. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast & Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
7. Wils J, Bliss JM, Coombes RC et al. A multicentre randomized trial of tamoxifen vs. tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 1996; 15: 109 (Abstr 101).
8. R and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: A Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 1997; 16: 128a (Abstr 450).
9. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1399-87.
10. Clahsen PC, Van de Velde CJH, Welvaart K. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node positive breast cancer: A joint European Organization for Research and Treatment of Cancer - Dutch Breast Cancer Working Party Study. J Clin Oncol 1995; 13: 33-41.
11. Zambetti M, Valagussa P, Bonadonna G. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Ann Oncol 1996; 7: 481-5.
12. Carmo-Pereira J, Costa FO, Henriques E, Carvalho V. A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer. Cancer Chemother Pharmacol 1986; 17: 87-90.
13. Brandi M, De Nitrio A, Ditonno Pet al. Oral versus intravenous CMF in metastatic breast cancer: A randomized trial. Int J Oncol 1994; 4: 559-65.
14. Engelsman E, Klijn JC, Rubens RD et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial (10808). Eur J Cancer 1991; 27: 966-70.
15. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-7.
16. Castiglione-Gertsch M, Johnsen C, Goldhirsch A et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994; 5: 717-24.
17. Boccardo F, Amoroso D, Rubagotti A et al. for the GROCTA. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: An update at 8 years of the first GROCTA trial. In Salmon SE (ed): Adjuvant Therapy of Cancer VII. Philadelphia: J.B. Lippincott 1993; 181-92.
18. Rivkin SE, Green S, Metch B et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study J Clin Oncol 1994; 12: 2078-85.
19. Rose C, Andersen J, Axelsson C, Blichert-Toft M. A randomized DBCG trial of adjuvant (adj) tamoxifen (TAM) + radiotherapy (RT) vs. TAM alone vs. TAM + CMF in postmenopausal breast cancer patients (pts) with high risk of recurrence (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1992; 11 (Abstr 57).
20. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-94.
21. Pritchard KI, Paterson AHG, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and or progesterone receptor-positive breast cancer. A report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 2302-11.
22. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82.
23. Fisher B, Dignam J, Mamounas EP et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 7: 1982-92.
24. Goldhirsch A, Colleoni M, Coates AC, Gelber RD. Chest wall radiation therapy for breast cancer (Letter). N Engl J Med 1998; 338: 330.
25. Goldhirsch A, Coates AS, Colleoni M et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: CMF dose and schedule may make a difference. J Clin Oncol 1998 (in press).